IM Cannabis Corp. (IMCC) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

IM Cannabis Corp. (IMCC) Healthcare & Pipeline Overview

IM Cannabis Corp. is a Tel Aviv-Yafo-based healthcare company specializing in the cultivation, production, and distribution of medicinal and recreational cannabis products across Israel, Germany, and Canada. The company leverages brands like IMC, WAGNERS, and Highland Grow to serve diverse consumer needs within the evolving global cannabis market.

What Is the Investment Thesis for IMCC?

IM Cannabis Corp. operates within the growing global cannabis market, positioning itself as an international provider of medicinal and recreational cannabis products across Israel, Germany, and Canada. The company's value proposition is underpinned by its diverse product portfolio, including flowers, extracts, pre-rolls, and hashish, marketed under established brands like IMC, WAGNERS, and Highland Grow. A key growth catalyst is the expanding global demand for cannabis, driven by increasing medical acceptance and ongoing recreational legalization efforts, which could open new geographic markets and enhance sales volumes. However, the investment thesis is tempered by significant risk factors, including the company's current unprofitability, evidenced by a -3.0% profit margin, and an extremely low market capitalization of $0.00 billion, which implies substantial liquidity risk. The high beta of 1.98 indicates considerable stock price volatility. Investors should closely monitor IM Cannabis Corp.'s ability to achieve profitability, manage its cash flow effectively, and navigate the intense competitive landscape and evolving regulatory environment to sustain long-term growth and enhance shareholder value.

Based on FMP financials and quantitative analysis

IMCC Key Highlights

Market Capitalization: $0.00 billion, indicating a market valuation below $1 million, which presents significant liquidity considerations.

• Gross Margin: 24.8%, reflecting the company's profitability at the production level before operating expenses.
• Profit Margin: -3.0%, indicating the company is currently operating at a net loss.
• Beta: 1.98, suggesting the stock's price is significantly more volatile than the overall market.
• Employee Base: Operates with a team of 95 employees, supporting its cultivation, production, and distribution activities across multiple countries.

Who Are IMCC's Competitors?

IMCC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are IMCC's Key Strengths?

Established international presence in key cannabis markets (Israel, Germany, Canada).

• Diverse product portfolio including flowers, extracts, pre-rolls, and hashish.
• Multiple distinct brands (IMC, WAGNERS, Highland Grow) catering to different market segments.
• Focus on premium quality cannabis products.

What Are IMCC's Weaknesses?

Negative profit margin (-3.0%) indicates current unprofitability.

• Extremely low market capitalization ($0.00B) suggests significant liquidity and funding challenges.
• High beta (1.98) implies substantial stock price volatility.
• Ongoing cash flow management challenges in a competitive industry.

What Could Drive IMCC Stock Higher?

IMCC catalyst: Potential regulatory liberalization in new European markets, opening new distribution channels for medical cannabis beyond Germany.

• Expansion of product lines to capture diverse consumer preferences, including new formulations or delivery methods, in existing markets.
• Strategic partnerships aimed at enhancing cultivation capacity, improving supply chain efficiency, or expanding market reach in Israel or Canada.
• Introduction of new cannabis formulations or cannabinoid-specific products to address evolving patient needs and market demands.
• Continued growth in demand for both medical and recreational cannabis products across its operational geographies.

What Are the Key Risks for IMCC?

Financial-distress signal — its Altman Z-Score of -16.08 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-24.4%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Significant liquidity risk due to the company's extremely low market capitalization of under $1 million, potentially impacting access to capital.
• Persistent unprofitability, evidenced by a -3.0% profit margin, posing challenges for sustainable operations and long-term financial health.
• Adverse regulatory changes or delays in market liberalization within key operating regions, which could restrict growth or increase compliance costs.
• Intense competition within the global cannabis industry, impacting market share, pricing power, and the ability to achieve economies of scale.
• Challenges in managing cash flow and securing additional funding for growth initiatives and operational stability amidst market volatility and investor scrutiny.

What Are the Growth Opportunities for IMCC?

• Geographic Expansion in Europe: With a current presence in Germany, IM Cannabis Corp. has a strategic foothold in the European medical cannabis market, which is projected for significant growth as more EU member states consider or implement medical cannabis programs. Expanding into additional European countries that are legalizing or liberalizing medical cannabis laws presents a substantial opportunity to leverage existing supply chains and regulatory expertise. This expansion could involve establishing new distribution partnerships or direct market entry, tapping into a patient population with increasing access to cannabis-based therapies and potentially diversifying revenue streams beyond current core markets.
• Product Diversification and Innovation: The cannabis market is continuously evolving, with consumer preferences shifting towards a wider array of product formats beyond traditional dried flower. IM Cannabis Corp. can capitalize on this trend by investing in research and development to introduce new product categories, such as advanced edibles, concentrates, topicals, or cannabinoid-specific formulations. Innovating within its IMC, WAGNERS, and Highland Grow brands would allow the company to capture new market segments, enhance customer loyalty, and potentially command higher margins for specialized products, thereby strengthening its competitive position in both medical and recreational sectors.
• Leveraging the Adult Recreational Market Expansion: IM Cannabis Corp. already participates in the adult recreational market in Canada through its WAGNERS and Highland Grow labels. As more jurisdictions globally move towards legalizing recreational cannabis, the company has an opportunity to expand its recreational brand presence into these new markets. This involves adapting its marketing and distribution strategies to meet the demands of adult consumers in diverse cultural and regulatory environments. Capitalizing on this trend could significantly increase sales volumes and market share, particularly in regions with large populations and favorable regulatory frameworks for recreational use.
• Strengthening Medical Cannabis Presence and Research: The medical cannabis segment offers stability and often higher margins due to its focus on patient needs and clinical efficacy. IM Cannabis Corp. can deepen its commitment to the medical market by investing in clinical research to validate the therapeutic benefits of its products, fostering stronger relationships with healthcare professionals, and expanding patient access programs in Israel and Germany. This approach not only reinforces its position as a trusted medical cannabis provider but also allows for the development of targeted formulations that address specific health conditions, potentially leading to increased market penetration and brand credibility within the healthcare community.
• Supply Chain Optimization and Vertical Integration: Enhancing efficiency across its cultivation, production, and distribution processes represents a significant growth opportunity. By optimizing its supply chain, IM Cannabis Corp. can reduce operational costs, improve gross margins, and ensure consistent product quality and availability. This could involve exploring further vertical integration, from seed to sale, to gain greater control over the entire production process. Such improvements would not only bolster profitability but also enhance the company's ability to scale operations efficiently and respond more agilely to market demands and competitive pressures, contributing to long-term financial health.

What Threats Does IMCC Face?

• Intense competition from established and emerging cannabis companies.
• Evolving and often restrictive regulatory landscapes across different countries.
• Challenges in achieving and sustaining profitability amidst operational costs and market pressures.
• Potential for dilution or difficulty in raising capital due to low market capitalization.

What Are IMCC's Competitive Advantages?

• Established international supply chains and distribution networks across Israel, Germany, and Canada, facilitating multi-market access.
• Brand recognition with distinct labels like IMC for medical products and WAGNERS/Highland Grow for recreational offerings.
• Diverse product portfolio catering to both medical patients and adult recreational consumers, broadening market reach.
• Expertise in the cultivation and production of specialty cannabis goods, ensuring product quality and consistency.

What Does IMCC Do?

IM Cannabis Corp. specializes in the cultivation, production, and provision of medicinal cannabis goods across key international markets, including Israel, Germany, and Canada. While the precise founding narrative and early evolution of the company are not detailed in the provided information, IM Cannabis Corp. has established itself as a significant player in the specialized drug manufacturing industry focused on cannabis. The company's core operations revolve around delivering a comprehensive range of cannabis products to both medical patients and adult recreational consumers. Under its flagship IMC brand, IM Cannabis Corp. offers high-quality cannabis flowers and specifically formulated cannabis extracts, catering to the medical segment with products designed for therapeutic use. Expanding its reach into the adult recreational market, the company also supplies dried flower, pre-rolled products, and compressed hashish through its distinct WAGNERS and Highland Grow labels. This dual-market approach allows IM Cannabis Corp. to address a broad customer base and capitalize on the growing demand for cannabis across different regulatory environments. Headquartered in Tel Aviv-Yafo, Israel, the company manages its international supply chains and distribution networks to ensure product availability and compliance in its operational regions. Its strategic positioning in these diverse markets underscores its commitment to navigating the complex global cannabis landscape and solidifying its presence as a provider of premium cannabis solutions.

What Products and Services Does IMCC Offer?

• Cultivates medicinal cannabis products.
• Produces a range of cannabis goods, including flowers and extracts.
• Provides medicinal cannabis products to international markets like Israel, Germany, and Canada.
• Offers specifically formulated cannabis extracts under its IMC brand.
• Supplies dried flower, pre-rolled products, and compressed hashish.
• Markets products under its WAGNERS and Highland Grow labels for recreational consumers.
• Serves both medical patients and adult recreational consumers.
• Operates its corporate headquarters from Tel Aviv-Yafo, Israel.

How Does IMCC Make Money?

• Generates revenue through the cultivation, production, and sale of medicinal cannabis flowers and extracts under the IMC brand.
• Earns income from the distribution and sale of dried flower, pre-rolled products, and compressed hashish to adult recreational markets via its WAGNERS and Highland Grow labels.
• Operates across multiple international jurisdictions, adapting its product offerings and distribution strategies to comply with diverse regulatory frameworks.
• Focuses on providing high-quality, specialty cannabis products to cater to specific patient and consumer demands in both medical and recreational segments.

What Industry Does IMCC Operate In?

IM Cannabis Corp. operates within the Drug Manufacturers - Specialty & Generic industry, specifically focusing on the cultivation, production, and distribution of cannabis products. This sector is characterized by rapid evolution, driven by shifting global perceptions and regulatory frameworks surrounding cannabis for both medicinal and adult recreational use. The overall market for cannabis is experiencing significant growth, with projections indicating continued expansion as more countries liberalize their laws. IM Cannabis Corp. positions itself as an international player, leveraging its presence in Israel, Germany, and Canada to tap into diverse consumer segments. The competitive landscape is intense, featuring numerous companies ranging from large, established cultivators to smaller, specialized producers. IM Cannabis Corp. aims to differentiate itself through its diverse product offerings and established brand presence in key international markets, navigating the complexities of regulatory compliance and market demand within this dynamic industry.

Who Are IMCC's Key Customers?

• Medical cannabis patients seeking therapeutic benefits for various conditions in Israel and Germany.
• Adult recreational consumers in legalized markets, primarily Canada.
• Wholesale distributors and licensed pharmacies in medical cannabis markets.
• Licensed retail dispensaries and provincial distributors in recreational cannabis markets.

Company Profile

IM Cannabis Corp. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Glil Yam, IL. The company is led by CEO Oren Shuster. IMCC has traded publicly since 2020.

IM Cannabis Corp.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -16.08 places it in the distress zone, a signal of elevated financial risk.

Return on equity for IM Cannabis Corp. stands at -24.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -2.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.72 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -6.9%, the inverse of the P/E and a quick read on earnings relative to price.

IMCC Valuation & Market Position

Relative to its peer group, IMCC's quantitative score of 44/100 is below the peer average of 62/100.

Wall Street analysts project IM Cannabis Corp. revenue of about $62.8M for fiscal 2026, with EPS near $-0.32.

IMCC Financials

IMCC Latest News

IMCC Analyst Consensus

IMCC MoonshotScore

Common Questions About IMCC (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources